Highest-materiality recent filing
Collegium closes $655.6M acquisition of AZSTARYS; Corium had going concern doubt
Acquired AZSTARYS (ADHD treatment) for ~$655.6M cash, funded by $355.6M cash on hand and $300M delayed draw term loan.
Collegium completes $650M acquisition of AZSTARYS; raises 2026 guidance
Acquired AZSTARYS from Corium Therapeutics for ~$650M cash; up to $135M in commercial/mfg milestones.
Product net revenue of $193.5M (+9% YoY); GAAP diluted EPS $0.40; adjusted EPS $1.76.
Collegium to acquire AZSTARYS for $650M cash; expected to close Q2 2026
Acquisition of AZSTARYS (ADHD treatment) for $650M cash, plus up to $135M in commercial and regulatory milestones.
Collegium Q4 net rev $205.4M (+13% YoY); FY 2025 rev $780.6M (+24%); reaffirms 2026 guidance
Q4 GAAP diluted EPS $0.46 vs $0.36 YoY; adjusted diluted EPS $2.04 vs $1.77.
Collegium Pharma guides FY2026 revenue $805-825M; Jornay PM $190-200M; adj. EBITDA $455-475M
Product revenue guidance $805-825M; Jornay PM net revenue $190-200M.
Collegium closes $980M syndicated credit facility, repays Pharmakon loan
$980M total facility: $580M term loan, $300M delayed draw, $100M revolver; matures 2030.
Collegium Q3 revenue $209.4M (+31% YoY); raises 2025 guidance
GAAP net income $31.5M ($0.84 diluted EPS); adj. net income $87.3M ($2.25 adj. EPS).
Collegium Q2 revenue $188M (+29% YoY); raises 2025 guidance; authorizes $150M buyback
Record quarterly product revenue $188.0M, up 29% YoY; GAAP EPS $0.34 diluted; adjusted EPS $1.68.
Collegium Pharmaceutical authorizes up to $150M share repurchase program through Dec 2026
Board authorized $150M share repurchase program, valid through Dec 31, 2026.
Shareholders approve 2025 Equity Incentive Plan authorizing 3.47M new shares
Shareholders voted 20.3M for, 7.1M against to approve the 2025 Equity Incentive Plan.
Collegium enters $25M accelerated share repurchase; 692,281 shares initially delivered
ASR with Jefferies for $25M; part of $150M repurchase program authorized Jan 2024.
Collegium Q1 revenue up 23% to $177.8M; guides FY25 $735-750M; authorizes $25M ASR
Q1 net revenue $177.8M (+23% YoY); Jornay PM $28.5M (+24% Rx growth); pain portfolio $149.2M (+3%).
Dr. Carlos Paya nominated for election to Board at 2025 Annual Meeting; current venture partner at Abingworth/Carlyle.
Collegium reports record Q4 revenue $181.9M, GAAP EPS $0.36; EVP Shirley Kuhlmann departing March 7
Q4 product revenue $181.9M (+22% YoY); GAAP net income $12.5M ($0.36 diluted EPS); adjusted EBITDA $107.7M.
Collegium provides 2025 guidance: product revenue $735M-$750M, adj EBITDA $435M-$450M
Product revenues, net expected $735M-$750M for 2025.
Acquisition closed Sept 3, 2024; Ironshore's JORNAY PM (ADHD) product revenue $78.6M in 2023, $43.8M in H1 2024.
Collegium posts record Q3 revenue $159.3M, up 17%; names Vikram Karnani CEO
Q3 net revenue $159.3M (record), up 17% YoY; GAAP net income $9.3M ($0.27 diluted EPS).
Collegium closes $525M Ironshore acquisition; adds Jornay PM, boosts 2024 outlook
Ironshore acquired for $525M cash plus potential $25M milestone based on Jornay PM 2025 net revenue.
Collegium Q2 revenue up 7% to $145.3M; adjusted EPS $1.62; Ironshore acquisition on track
Net revenue $145.3M (+7% YoY); Belbuca record $52.2M (+21% YoY); GAAP net income $19.6M (+51% YoY).
Collegium to acquire Ironshore Therapeutics for $525M; Jornay PM ADHD drug; Q2 prelim rev $145M
Acquires Ironshore for $525M cash plus up to $25M milestone if Jornay PM net revenue exceeds defined 2025 threshold.
FDA grants pediatric exclusivity for Nucynta franchise; exclusivity extended to Jan 2027
FDA granted pediatric exclusivity for Nucynta and Nucynta ER; Nucynta exclusivity now to Jan 3, 2027, Nucynta ER to Dec 27, 2025.
CEO Joseph Ciaffoni steps down; Chairman Michael Heffernan named Interim CEO
Joseph Ciaffoni to step down as President and CEO effective May 24, 2024.
Collegium Q1 net revenue $144.9M, GAAP net income $27.7M, CEO steps down May 24
GAAP net income of $27.7M ($0.71 diluted EPS) vs. loss of $(17.4M) in Q1 2023.
Collegium enters authorized generic agreement with Hikma for Nucynta IR and ER
Hikma gains exclusive US marketing rights for authorized generics of Nucynta IR and ER; launch 30 days before LOE.
Collegium Pharma reports record Q4/FY2023 revenue; GAAP net income of $31.9M Q4, $48.2M FY
Record Q4 revenue $149.7M (+16% YoY); FY revenue $566.8M (+22% YoY).
Collegium 2024 guidance: revenue $580-595M, adj. EBITDA $380-395M, $150M buyback
FY2024 product revenue net expected $580M-$595M; adjusted EBITDA $380M-$395M.
Collegium Q3 revenue $136.7M (+8% YoY), adj. EBITDA record $89.4M, guidance tightened
GAAP net income $20.6M vs $0.5M; diluted EPS $0.53; adjusted EPS $1.34.
FDA grants Nucynta IR exclusivity extension to July 2026
FDA granted New Patient Population exclusivity for Nucynta (tapentadol IR), extending U.S. exclusivity from June 27, 2025 to July 3, 2026.
Collegium enters $50M accelerated share repurchase under $100M buyback program
$50 million ASR agreement with Jefferies LLC; initial delivery of ~1.7M shares (80% of expected) based on $23.49 close
Collegium Q2 net revenue $135.5M (+10% YoY); GAAP net income $13.0M vs loss; authorizes $50M buyback
Q2 GAAP net income $13.0M ($0.34 diluted EPS) vs GAAP net loss of $5.2M a year ago; adjusted EBITDA $85.8M, up 21% YoY.
Collegium reports record Q1 revenue $144.8M, adjusted EPS $1.32, reaffirms FY23 guide
Record product revenue net of $144.8M, up 73% YoY from $83.8M.
Collegium Q4 record net revenue $129.6M; FY22 adj. EBITDA $266.0M, reaffirms 2023 guidance
Q4 product revenue $129.6M (up from $27.4M YoY); GAAP net loss $(7.2)M vs $(25.0)M YoY.
Collegium prices $241.5M convertible notes offering, repurchases $117.4M of 2026 notes
Priced $210M convertible notes offering, upsized to $241.5M with full exercise of initial purchasers' option.
Collegium prelim Q4/FY22 revenue at high-end of guidance; announces $175M convertible notes offering
Prelim FY22 product revenue $460.0M-$462.5M; Q4 $125.7M-$128.2M; both at or above prior guidance high-end.
Collegium provides 2023 guidance: rev $565-580M, adj EBITDA $355-370M, $100M buyback
Product revenue net expected $565-580M for 2023, up from ~$460M in 2022.
Federal Circuit upholds Collegium's Belbuca patents; blocks Alvogen generic until 2032
Alvogen conceded infringement; Federal Circuit ruling bars generic entry until 2032 patent expiry (9,901,539 patent).
Record Q3 revenue $127.0M (+61% YoY); GAAP net income $0.5M ($0.01 EPS), adj. net income $42.5M ($1.10 adj. EPS).
Collegium Q2 revenue $123.5M record, raises FY Adj EBITDA guidance to $245-255M
Q2 net product revenue $123.5M (record), up from $82.9M YoY.
Collegium files BDSI acquisition pro forma; $669M total consideration, $75M annual synergy target
Total consideration for BDSI acquisition: $669.4M ($606.4M cash to stockholders at $5.60/share + $63.0M to retire BDSI debt).
Thomas Smith, M.D., Executive Vice President and Chief Medical Officer of the Company will depart from his positions at the Company following a transition period during which the Company will conduct a search for his successor.
Scott Dreyer, Executive Vice President and Chief Commercial Officer of the Company will depart from his positions at the Company effective August 30, 2026.
approved the nomination of Dr. Carlos Paya to stand for election
Gwen Melincoff also advised the Board that she will not stand for re-election at the Annual Meeting and will retire from the Board at that time.
Michael Heffernan, R.Ph., founder and current Chairman of the Board advised the Board that he will not stand for re-election at the Annual Meeting and will retire from the Board at that time.
The Board has named Gino Santini, the Company’s lead independent director since 2018, as Chairman of the Board, effective immediately following the Company’s Annual Meeting.
On February 27, 2025, the Company announced that Shirley Kuhlmann, Executive Vice President, Chief Administrative Officer, General Counsel & Secretary of the Company will step down from her positions at the Company effective March 7, 2025.
approved the expansion of the Board from eight directors to nine directors and the appointment of Nancy Lurker to serve as a director of the Board, effective as of February 4, 2025
the Board of Directors (the “Board”) of the Company appointed Vikram Karnani to serve as the Company’s President and Chief Executive Officer, effective November 12, 2024
Concurrently with his appointment as President and Chief Executive Officer and effective as of the Effective Date, Mr. Karnani will be appointed to serve as a member of the Board
succeeding Michael Heffernan, who will continue to serve as the Company’s Chairman of the Board.
On July 28, 2024, Neil McFarlane notified the board of directors of the Company (the “Board”) of his intent to resign from the Board, effective immediately.
Max materiality 1.00 · Median 0.75 · Most common event earnings